From: The role of opioids in cancer response to immunotherapy
 | Total | OPIODS | NO OPIODS | p | |
---|---|---|---|---|---|
N. (%) | N. (%) | N. (%) | |||
193 (100) | 42 (100) | 151 (100) | |||
Sex | Â | ||||
 Male | 120 (62) | 25 (60) | 95(63) | 0.689 | |
 Female | 73 (38) | 17 (40) | 56 (37) |  | |
Age (years) | Â | ||||
Median | Â | Â | Â | Â | |
 < 65 | 61 (32) | 14 (33) | 47 (31) |  | |
 65–75 | 78 (40) | 21 (50) | 57 (38) 57 (38) |  | |
 > 75 | 53 (53) | 7 (17) | 46 (31) | 0.171 | |
Missed | 1 (1) | Â | Â | Â | |
Diagnosis | Â | Â | Â | Â | |
 NSCLC | 59 (30) | 21(62) | 33 (22) |  < 0.0001 | |
 Melanoma | 99 (51) | 7 (17) | 92 (61) |  | |
 Renal Cancer | 28 (14) | 5 (12) | 23 (15) |  | |
 Urothelial Cancer | 5 (3) | 3 (7) | 2 (1) |  | |
 Merkel Tumor | 1 (0.5) | 1 (2) | 0 |  | |
 Colon Cancer | 1 (0.5) | 0 | 1 (1) |  | |
ECOG PS | |||||
 0 | 94 (49) | 9 (21) | 85 (56) |  | |
 ≥1 | 99 (51) | 33 (79) | 66 (44) |  < 0.0001 | |
Comorbidity | |||||
 0–1 | 122 (63) | 29 (69) | 93 (62) | 0.375 | |
 ≥2 | 71 (37) | 13 (31) | 58 (38) |  | |
Immunotherapy, drug name | |||||
 Nivolumab | 121 (63) | 26 (62) | 95 (63) | 0.145 | |
 Pembrolizumab | 60 (31) | 11 (26) | 49 (32) |  | |
 Atezolizumab | 11 (6) | 4 (10) | 7 (5) |  | |
 Avelumab | 1 (0.5) | 1 (2) | 0 |  | |
Immunotherapy setting | |||||
 First line | 91 (47) | 11 (26) | 80 (53) |  | |
 Second line | 69 (36) | 21 (50) | 48 (32) | 0.009 | |
 Beyond II-line | 33 (17) | 10 (24) | 23 (15) |  | |
Antibiotics/Antifungals | |||||
 Yes | 21 (11) | 8 (19) | 13 (9) | 0.055 | |
 Not | 172 (89) | 34 (81) | 138 (91) |  | |
Corticosteroids | |||||
 Yes | 44 (23) | 20 (48) | 24 (16) |  < 0.0001 | |
 Not | 148 (77) | 22 (52) | 126 (84) |  | |
Opiods | |||||
Yes | 42 (22) | - | - | Â | |
Not | 151 (78) | - | - | Â | |
Tumor burden | |||||
 Low | 91 (47) | 12 (29) | 79 (52) |  | |
 High | 102 (53) | 30 (71) | 72 (48) | 0.006 |